MCID: GLL008
MIFTS: 63

Gilles De La Tourette Syndrome

Categories: Rare diseases, Mental diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

MalaCards integrated aliases for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 57 12 25 75 15 40 73
Tourette Syndrome 57 12 76 53 25 54 37 29 13 55 6 43 3 44
Gilles De La Tourette's Syndrome 76 53 25
Tourette Disorder 57 53 25
Gts 57 25 75
Ts 57 25 3
Chronic Motor and Vocal Tic Disorder 25
Motor-Verbal Tic Disorder 12
Tourette Syndrome; Ts 57
Tourette's Syndrome 53
Tourette's Disease 25
Guinon's Disease 12
Psychogenic Tics 12
Td 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
male:female ratio 4:1
onset ages 2 to 14 years


HPO:

32
gilles de la tourette syndrome:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Gilles De La Tourette Syndrome

NIH Rare Diseases : 53 Tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. Tourette syndrome is named for Georges Gilles de la Tourette, who first described this disorder in 1885. A variety of genetic and environmental factors likely play a role in causing Tourette syndrome. A small number of people with Tourette syndrome have been found to have mutations involving the SLITRK1 gene. The syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. It is estimated that about 1% of the population has Tourette syndrome. Many people with very mild tics may not be aware of them and never seek medical help. Tourette syndrome is four times as likely to occur in boys as in girls. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

MalaCards based summary : Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to movement disease and impulse control disorder, and has symptoms including athetosis, back pain and headache. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways/superpathways are Histidine metabolism and Amphetamine addiction. The drugs Clonidine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and cortex, and related phenotypes are sleep disturbance and attention deficit hyperactivity disorder

Disease Ontology : 12 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

Genetics Home Reference : 25 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood.

OMIM : 57 Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with behavioral abnormalities. Tics are sudden, brief, intermittent, involuntary or semi-voluntary movements (motor tics) or sounds (phonic or vocal tics). They typically consist of simple, coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. Motor tics may range from simple blinking, nose twitching, and head jerking to more complex throwing, hitting, or making rude gestures. Phonic tics include sniffling, throat clearing, blowing, coughing, echolalia, or coprolalia. Males are affected about 3 times more often than females, and onset usually occurs between 3 and 8 years of age. By age 18 years, more than half of affected individuals are free of tics, but they may persist into adulthood (review by Jankovic, 2001). (137580)

MedlinePlus : 43 If you have Tourette syndrome, you make unusual movements or sounds, called tics. You have little or no control over them. Common tics are throat-clearing and blinking. You may repeat words, spin, or, rarely, blurt out swear words. Tourette syndrome is a disorder of the nervous system. It often occurs with other problems, such as Attention deficit hyperactivity disorder (ADHD) Obsessive-compulsive disorder (OCD) Anxiety Depression The cause of Tourette syndrome is unknown. It is more common in boys than girls. The tics usually start in childhood and may be worst in the early teens. Many people eventually outgrow them. No treatment is needed unless the tics interfere with everyday life. Excitement or worry can make tics worse. Calm, focused activities may make them better. Medicines and talk therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Tourette Syndrome (TS) causes people to have “tics”. Tics are sudden twitches, movements, or sounds that people do repeatedly. People who have tics cannot stop their body from doing these things.

NINDS : 54 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood.  Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others).  Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

UniProtKB/Swiss-Prot : 75 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

Wikipedia : 76 Tourette syndrome (TS or simply Tourette\'s) is a common neuropsychiatric disorder with onset in... more...

Related Diseases for Gilles De La Tourette Syndrome

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 movement disease 31.4 DRD2 SGCE SLC6A3
2 impulse control disorder 31.4 DRD2 DRD4 SLITRK1
3 tardive dyskinesia 31.2 COMT DRD2
4 dystonia 30.8 DRD2 DRD5 SGCE SLC6A3
5 major depressive disorder 30.5 BDNF COMT DRD2 DRD4 SLC6A3
6 obsessive-compulsive disorder 30.5 BDNF COMT DRD2 DRD4 SGCE SLC6A3
7 autism 30.3 BDNF CNTNAP2 COMT DRD2 DRD4 IMMP2L
8 tic disorder 30.2 DRD2 DRD4 DRD5 HDC IMMP2L SLC6A3
9 schizophrenia 29.5 BDNF CNTNAP2 COMT DBH DRD2 DRD4
10 glanzmann thrombasthenia 11.8
11 turner syndrome 11.8
12 virus-associated trichodysplasia spinulosa 11.6
13 cholestasis, progressive familial intrahepatic, 1 11.5
14 trichotillomania 11.4
15 lymphoma, hodgkin, classic 11.2
16 mitochondrial dna depletion syndrome 7 11.2
17 tuberous sclerosis 1 11.1
18 timothy syndrome 11.1
19 cholestasis, benign recurrent intrahepatic, 1 11.1
20 trichostasis spinulosa 11.1
21 temperature sensitivity complementation, cell cycle specific, k12 11.0
22 focal facial dermal dysplasia 3, setleis type 10.9
23 kleefstra syndrome 10.9
24 albinism, oculocutaneous, type ib 10.9
25 tuberous sclerosis 2 10.9
26 alcohol-induced mental disorder 10.8 DRD2 SLC6A3
27 schizophreniform disorder 10.8 COMT DRD2
28 pathological gambling 10.8 DRD2 DRD4 SLC6A3
29 mutism 10.8 CNTNAP2 SLC6A3
30 perry syndrome 10.7
31 ritscher-schinzel syndrome 1 10.7
32 bile acid synthesis defect, congenital, 2 10.7
33 hyperparathyroidism, neonatal severe 10.7
34 mucopolysaccharidosis type vi 10.7
35 myopathy, lactic acidosis, and sideroblastic anemia 1 10.7
36 acromesomelic dysplasia, maroteaux type 10.7
37 bile acid synthesis defect, congenital, 1 10.7
38 mitochondrial trifunctional protein deficiency 10.7
39 leukocyte adhesion deficiency, type iii 10.7
40 adenine phosphoribosyltransferase deficiency 10.7
41 cocaine abuse 10.7 DBH DRD2 SLC6A3
42 antisocial personality disorder 10.7 COMT DRD2 SLC6A3
43 polysubstance abuse 10.7 COMT DRD2
44 cocaine dependence 10.7 DBH DRD2 SLC6A3
45 multiple system atrophy 1 10.7 DBH DRD2 SLC6A3
46 delusional disorder 10.7 DRD2 DRD4
47 migraine with aura 10.7 DBH DRD2 SLC6A3
48 heroin dependence 10.6 BDNF DRD2 DRD4
49 dystonia 11, myoclonic 10.6 DBH DRD2 SGCE
50 stuttering 10.6 CNTNAP2 DBH DRD2 SLC6A3

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to Gilles De La Tourette Syndrome

Symptoms & Phenotypes for Gilles De La Tourette Syndrome

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
sleep disturbance
obsessive-compulsive behavior
aggressive behavior
echolalia
coprolalia
more

Clinical features from OMIM:

137580

Human phenotypes related to Gilles De La Tourette Syndrome:

32 (show all 8)
# Description HPO Frequency HPO Source Accession
1 sleep disturbance 32 HP:0002360
2 attention deficit hyperactivity disorder 32 HP:0007018
3 obsessive-compulsive behavior 32 HP:0000722
4 aggressive behavior 32 HP:0000718
5 echolalia 32 HP:0010529
6 self-mutilation 32 HP:0000742
7 motor tics 32 HP:0100034
8 phonic tics 32 HP:0100035

UMLS symptoms related to Gilles De La Tourette Syndrome:


athetosis, back pain, headache, pain, sciatica, seizures, sleep disturbances, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 ADRA1A ADRA2A BDNF BTBD9 CNTNAP2 COMT
2 homeostasis/metabolism MP:0005376 9.93 ADRA1A ADRA2A BDNF BTBD9 COMT DBH
3 nervous system MP:0003631 9.8 DRD2 DRD4 DRD5 HDC HMBS SGCE
4 taste/olfaction MP:0005394 8.92 BDNF CNTNAP2 DRD2 SLC6A3

Drugs & Therapeutics for Gilles De La Tourette Syndrome

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
3
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
4 Piracetam Approved, Investigational Phase 4 7491-74-9
5
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519
6
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
7
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
8
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
9
Haloperidol Approved Phase 4 52-86-8 3559
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Ondansetron Approved Phase 4 99614-02-5 4595
12
Galantamine Approved Phase 4 357-70-0 9651
13
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
14
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
15 Etiracetam Investigational Phase 4 33996-58-6
16 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Adrenergic Agonists Phase 4,Phase 3
18 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3
19 Adrenergic alpha-Agonists Phase 4,Phase 3
20 Analgesics Phase 4,Phase 3
21 Antihypertensive Agents Phase 4,Phase 3
22 Autonomic Agents Phase 4,Phase 1
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Not Applicable
25 Sympatholytics Phase 4
26 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Cholinergic Agents Phase 4,Not Applicable
28 Antipsychotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Tranquilizing Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
32 Excitatory Amino Acid Agonists Phase 4
33 Excitatory Amino Acid Antagonists Phase 4
34 Excitatory Amino Acids Phase 4
35 Neuroprotective Agents Phase 4,Phase 3
36 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Nootropic Agents Phase 4
38 Anti-Anxiety Agents Phase 4
39 Antidepressive Agents Phase 4
40 Antidepressive Agents, Second-Generation Phase 4
41 Antiemetics Phase 4
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
43 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
44 Cytochrome P-450 Enzyme Inhibitors Phase 4
45 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46 Dopamine Antagonists Phase 4,Phase 3,Phase 1,Phase 2
47 Gastrointestinal Agents Phase 4
48 Haloperidol decanoate Phase 4
49 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
50 Serotonin Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 148)
# Name Status NCT ID Phase Drugs
1 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
2 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
3 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
4 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
5 Guanfacine in Children With Tic Disorders Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
6 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
7 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
8 Safety Study of Galantamine in Tic Disorders Terminated NCT00226824 Phase 4 galantamine
9 Pallidal Stimulation and Gilles de la Tourette Syndrome Completed NCT00478842 Phase 3
10 Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01416441 Phase 3 aripiprazole
11 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418352 Phase 3 aripiprazole 52.5 mg;Matching Placebo;Aripiprazole 77.5 mg;Aripiprazole 110 mg
12 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418339 Phase 3 aripiprazole;Placebo
13 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
14 Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
15 A Randomized, Placebo-controlled, Tourette Syndrome Study. Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
16 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Completed NCT00206336 Phase 3 Topiramate (drug)
17 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
18 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
19 Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children Completed NCT00218777 Phase 2, Phase 3
20 Phase III Study of 5LGr to Treat Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
21 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
22 Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents. Recruiting NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
23 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome Recruiting NCT03066193 Phase 3 Dronabinol
24 A Study to Evaluate the Safety and Tolerability of Long-term Therapy With TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo
25 CANNAbinoids in the Treatment of TICS (CANNA-TICS) Recruiting NCT03087201 Phase 3 nabiximols;placebo
26 Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome Not yet recruiting NCT03487783 Phase 3 Aripiprazole Oral Solution;Placebo Oral Solution
27 A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome Not yet recruiting NCT03571256 Phase 3 deutetrabenazine Low;deutetrabenazine High;Placebo
28 Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome Terminated NCT00681863 Phase 3 pramipexole 0.125 mg BID;pramipexole 0.0625 mg QD;pramipexole 0.125 mg TID;pramipexole 0.25 mg BID;pramipexole 0.0625 mg BID
29 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome Unknown status NCT02112253 Phase 1, Phase 2
30 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
31 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
32 A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome Completed NCT02217007 Phase 2 SNC-102 sustained release tablet
33 Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
34 Subthalamic Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
35 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Completed NCT02581865 Phase 2 NBI-98854;Placebo
36 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome Completed NCT02679079 Phase 2 NBI-98854;Placebo
37 VoIP Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
38 Ecopipam Treatment of Tourette Syndrome Completed NCT01244633 Phase 1, Phase 2 Ecopipam
39 A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome Completed NCT01647269 Phase 2
40 Thalamic Deep Brain Stimulation for Tourette Syndrome Completed NCT00311909 Phase 2
41 N-acetylcysteine (NAC) for Children With Tourette Syndrome Completed NCT01172288 Phase 2 N-Acetylcysteine (NAC);Placebo
42 Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria Completed NCT00558467 Phase 2 pramipexole immediate release (IR);Placebo
43 Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome Completed NCT00529308 Phase 2
44 Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
45 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Completed NCT02879578 Phase 2 NBI-98854
46 Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome Completed NCT00004393 Phase 2 risperidone
47 Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome Completed NCT00004652 Phase 2 pimozide
48 Safety and Efficacy of Cannabis in Tourette Syndrome Recruiting NCT03247244 Phase 2 Cannabis;Cannabis;Cannabis
49 Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Recruiting NCT03530293 Phase 2 Valbenazine;Placebo oral capsule
50 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Recruiting NCT03325010 Phase 2 Valbenazine;Placebo oral capsule

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

Genetic tests related to Gilles De La Tourette Syndrome:

# Genetic test Affiliating Genes
1 Tourette Syndrome 29 HDC SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

41
Brain, Eye, Cortex, Thalamus, Globus Pallidus, Testes, Colon

Publications for Gilles De La Tourette Syndrome

Articles related to Gilles De La Tourette Syndrome:

(show top 50) (show all 638)
# Title Authors Year
1
A Randomized Controlled Trial Comparing Behavioral, Educational, and Pharmacological Treatments in Youths With Chronic Tic Disorder or Tourette Syndrome. ( 29636706 )
2018
2
Gilles de la Tourette syndrome as a paradigmatic neuropsychiatric disorder. ( 29781408 )
2018
3
Is procedural memory enhanced in Tourette syndrome? Evidence from a sequence learning task. ( 28964503 )
2018
4
Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. ( 28651666 )
2018
5
Altered perception-action binding modulates inhibitory control in Gilles de la Tourette syndrome. ( 29924402 )
2018
6
Efficacy of a Gluten-Free Diet in the Gilles de la Tourette Syndrome: A Pilot Study. ( 29735930 )
2018
7
Implicit sequence learning in young people with Tourette syndrome with and without co-occurring attention-deficit/hyperactivity disorder. ( 29972622 )
2018
8
Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option. ( 29154107 )
2018
9
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. ( 29340590 )
2018
10
Seroprevalance Anti-Toxoplasma gondii antibodies in children and adolescents with tourette syndrome/chronic motor or vocal tic disorder: A case-control study. ( 29554545 )
2018
11
Inter-hemispheric Intrinsic Connectivity as a Neuromarker for the Diagnosis of Boys with Tourette Syndrome. ( 27011382 )
2017
12
Specific executive control impairments in Tourette syndrome: The role of response inhibition. ( 28039814 )
2017
13
Tourette Syndrome and Chronic Tic Disorders: The Clinical Spectrum Beyond Tics. ( 28805580 )
2017
14
Identification of candidate genes involved in the etiology of sporadic Tourette syndrome by exome sequencing. ( 28608572 )
2017
15
Putting the Pieces Together in Gilles de la Tourette Syndrome: Exploring the Link Between Clinical Observations and the Biological Basis of Dysfunction. ( 27783238 )
2017
16
Abnormal lateralization of fine motor actions in Tourette syndrome persists into adulthood. ( 28708864 )
2017
17
Procedural learning in Tourette syndrome, ADHD, and comorbid Tourette-ADHD: Evidence from a probabilistic sequence learning task. ( 28710940 )
2017
18
Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. ( 28641109 )
2017
19
Parental age and the risk of obsessive compulsive disorder and Tourette syndrome / chronic tic disorder in a nationwide population-based sample. ( 28738196 )
2017
20
Gilles de la Tourette syndrome. ( 28150696 )
2017
21
Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group. ( 28887904 )
2017
22
Evidence for enhanced multi-component behaviour in Tourette syndrome - an EEG study. ( 28798371 )
2017
23
Parental Psychopathology and Tourette Syndrome/Chronic Tic Disorder in Offspring: A Nationwide Case-Control Study. ( 28335873 )
2017
24
Cognitive flexibility and its electrophysiological correlates in Gilles de la Tourette syndrome. ( 28863370 )
2017
25
Brain structure in pediatric Tourette syndrome. ( 27777415 )
2017
26
Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. ( 28007998 )
2017
27
Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome. ( 28387387 )
2017
28
Toward a Symptom-Guided Neurostimulation for Gilles de la Tourette Syndrome. ( 28289393 )
2017
29
Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study. ( 28816926 )
2017
30
Gilles de la Tourette syndrome. ( 28150698 )
2017
31
Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. ( 28445405 )
2017
32
Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome. ( 28740149 )
2017
33
Pediatric Tourette Syndrome: A Tic Disorder with a Tricky Presentation. ( 28611559 )
2017
34
A tug of war: antagonistic effective connectivity patterns over the motor cortex and the severity of motor symptoms in Gilles de la Tourette syndrome. ( 28833746 )
2017
35
Editorial: The Neurobiology and Genetics of Gilles de la Tourette Syndrome: New Avenues through Large-Scale Collaborative Projects. ( 29075205 )
2017
36
Gilles de la Tourette Syndrome, Depression, Depressive Illness, and Correlates in a Child and Adolescent Population. ( 28099039 )
2017
37
Altered topology of structural brain networks in patients with Gilles de la Tourette syndrome. ( 28878322 )
2017
38
Prevalence and predictors of hair pulling disorder and excoriation disorder in Tourette syndrome. ( 29098466 )
2017
39
Antipsychotic-induced hyperprolactinemia in Tourette syndrome. ( 28740637 )
2017
40
Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder. ( 28574423 )
2017
41
Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. ( 28796166 )
2017
42
Impact of Perceived Stress, Anxiety-Depression and Social Support on Coping Strategies of Parents Having A Child With Gilles de la Tourette Syndrome. ( 26804511 )
2016
43
BDNF and LTP-/LTD-like plasticity of the primary motor cortex in Gilles de la Tourette syndrome. ( 27900437 )
2016
44
Deutetrabenazine in Tics Associated with Tourette Syndrome. ( 27917309 )
2016
45
The relationship between tics, OC, ADHD and autism symptoms: A cross- disorder symptom analysis in Gilles de la Tourette syndrome patients and family-members. ( 26826899 )
2016
46
Microglial Dysregulation in OCD, Tourette Syndrome, and PANDAS. ( 28053994 )
2016
47
Deep Brain Stimulation in Gilles de la Tourette Syndrome: What Does the Future Hold? A Cohort of 48 Patients. ( 26348012 )
2016
48
Investigation of SNP rs2060546 Immediately Upstream to NTN4 in a Danish Gilles de la Tourette Syndrome Cohort. ( 27920664 )
2016
49
The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. ( 26880181 )
2016
50
The English Version of the Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL): A Validation Study in the United Kingdom. ( 27686095 )
2016

Variations for Gilles De La Tourette Syndrome

ClinVar genetic disease variations for Gilles De La Tourette Syndrome:

6
(show top 50) (show all 118)
# Gene Variation Type Significance SNP ID Assembly Location
1 SLITRK1 NM_052910.2(SLITRK1): c.1264delC (p.Leu422Phefs) deletion Pathogenic rs193302861 GRCh37 Chromosome 13, 84454379: 84454379
2 SLITRK1 NM_052910.2(SLITRK1): c.1264delC (p.Leu422Phefs) deletion Pathogenic rs193302861 GRCh38 Chromosome 13, 83880244: 83880244
3 SLITRK1 NM_052910.2(SLITRK1): c.*689G> A single nucleotide variant Pathogenic rs191284403 GRCh37 Chromosome 13, 84452863: 84452863
4 SLITRK1 NM_052910.2(SLITRK1): c.*689G> A single nucleotide variant Pathogenic rs191284403 GRCh38 Chromosome 13, 83878728: 83878728
5 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh37 Chromosome 15, 50544717: 50544717
6 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh38 Chromosome 15, 50252520: 50252520
7 SLITRK1 NM_052910.2(SLITRK1): c.*2043delT deletion Likely benign rs66938370 GRCh37 Chromosome 13, 84451509: 84451509
8 SLITRK1 NM_052910.2(SLITRK1): c.*2043delT deletion Likely benign rs66938370 GRCh38 Chromosome 13, 83877374: 83877374
9 SLITRK1 NM_052910.2(SLITRK1): c.*1882A> T single nucleotide variant Uncertain significance rs886050327 GRCh38 Chromosome 13, 83877535: 83877535
10 SLITRK1 NM_052910.2(SLITRK1): c.*1882A> T single nucleotide variant Uncertain significance rs886050327 GRCh37 Chromosome 13, 84451670: 84451670
11 SLITRK1 NM_052910.2(SLITRK1): c.*1572C> G single nucleotide variant Uncertain significance rs368937569 GRCh37 Chromosome 13, 84451980: 84451980
12 SLITRK1 NM_052910.2(SLITRK1): c.*1572C> G single nucleotide variant Uncertain significance rs368937569 GRCh38 Chromosome 13, 83877845: 83877845
13 SLITRK1 NM_052910.2(SLITRK1): c.*1160G> A single nucleotide variant Likely benign rs9602286 GRCh38 Chromosome 13, 83878257: 83878257
14 SLITRK1 NM_052910.2(SLITRK1): c.*1160G> A single nucleotide variant Likely benign rs9602286 GRCh37 Chromosome 13, 84452392: 84452392
15 SLITRK1 NM_052910.2(SLITRK1): c.*1149dupT duplication Uncertain significance rs886050328 GRCh38 Chromosome 13, 83878268: 83878268
16 SLITRK1 NM_052910.2(SLITRK1): c.*1149dupT duplication Uncertain significance rs886050328 GRCh37 Chromosome 13, 84452403: 84452403
17 SLITRK1 NM_052910.2(SLITRK1): c.*1134T> C single nucleotide variant Likely benign rs3737193 GRCh38 Chromosome 13, 83878283: 83878283
18 SLITRK1 NM_052910.2(SLITRK1): c.*1134T> C single nucleotide variant Likely benign rs3737193 GRCh37 Chromosome 13, 84452418: 84452418
19 SLITRK1 NM_052910.2(SLITRK1): c.*575C> T single nucleotide variant Uncertain significance rs886050329 GRCh38 Chromosome 13, 83878842: 83878842
20 SLITRK1 NM_052910.2(SLITRK1): c.*575C> T single nucleotide variant Uncertain significance rs886050329 GRCh37 Chromosome 13, 84452977: 84452977
21 SLITRK1 NM_052910.2(SLITRK1): c.913C> G (p.Pro305Ala) single nucleotide variant Uncertain significance rs867766209 GRCh38 Chromosome 13, 83880595: 83880595
22 SLITRK1 NM_052910.2(SLITRK1): c.913C> G (p.Pro305Ala) single nucleotide variant Uncertain significance rs867766209 GRCh37 Chromosome 13, 84454730: 84454730
23 SLITRK1 NM_052910.2(SLITRK1): c.-245dupT duplication Uncertain significance rs771177138 GRCh37 Chromosome 13, 84455887: 84455887
24 SLITRK1 NM_052910.2(SLITRK1): c.-245dupT duplication Uncertain significance rs771177138 GRCh38 Chromosome 13, 83881752: 83881752
25 SLITRK1 NM_052910.2(SLITRK1): c.-270delT deletion Uncertain significance rs886050341 GRCh37 Chromosome 13, 84455912: 84455912
26 SLITRK1 NM_052910.2(SLITRK1): c.-270delT deletion Uncertain significance rs886050341 GRCh38 Chromosome 13, 83881777: 83881777
27 SLITRK1 NM_052910.2(SLITRK1): c.-584T> G single nucleotide variant Uncertain significance rs886050344 GRCh37 Chromosome 13, 84456226: 84456226
28 SLITRK1 NM_052910.2(SLITRK1): c.-584T> G single nucleotide variant Uncertain significance rs886050344 GRCh38 Chromosome 13, 83882091: 83882091
29 SLITRK1 NM_052910.2(SLITRK1): c.-729G> C single nucleotide variant Uncertain significance rs774658734 GRCh38 Chromosome 13, 83882236: 83882236
30 SLITRK1 NM_052910.2(SLITRK1): c.-729G> C single nucleotide variant Uncertain significance rs774658734 GRCh37 Chromosome 13, 84456371: 84456371
31 SLITRK1 NM_052910.2(SLITRK1): c.*2186T> A single nucleotide variant Uncertain significance rs886050326 GRCh37 Chromosome 13, 84451366: 84451366
32 SLITRK1 NM_052910.2(SLITRK1): c.*2186T> A single nucleotide variant Uncertain significance rs886050326 GRCh38 Chromosome 13, 83877231: 83877231
33 SLITRK1 NM_052910.2(SLITRK1): c.*2087T> C single nucleotide variant Uncertain significance rs182027644 GRCh37 Chromosome 13, 84451465: 84451465
34 SLITRK1 NM_052910.2(SLITRK1): c.*2087T> C single nucleotide variant Uncertain significance rs182027644 GRCh38 Chromosome 13, 83877330: 83877330
35 SLITRK1 NM_052910.2(SLITRK1): c.*2042T> A single nucleotide variant Likely benign rs1046202 GRCh37 Chromosome 13, 84451510: 84451510
36 SLITRK1 NM_052910.2(SLITRK1): c.*2042T> A single nucleotide variant Likely benign rs1046202 GRCh38 Chromosome 13, 83877375: 83877375
37 SLITRK1 NM_052910.2(SLITRK1): c.*1944A> G single nucleotide variant Uncertain significance rs543615109 GRCh37 Chromosome 13, 84451608: 84451608
38 SLITRK1 NM_052910.2(SLITRK1): c.*1944A> G single nucleotide variant Uncertain significance rs543615109 GRCh38 Chromosome 13, 83877473: 83877473
39 SLITRK1 NM_052910.2(SLITRK1): c.*1313C> G single nucleotide variant Uncertain significance rs140472390 GRCh38 Chromosome 13, 83878104: 83878104
40 SLITRK1 NM_052910.2(SLITRK1): c.*1313C> G single nucleotide variant Uncertain significance rs140472390 GRCh37 Chromosome 13, 84452239: 84452239
41 SLITRK1 NM_052910.2(SLITRK1): c.*649A> G single nucleotide variant Uncertain significance rs57857456 GRCh38 Chromosome 13, 83878768: 83878768
42 SLITRK1 NM_052910.2(SLITRK1): c.*649A> G single nucleotide variant Uncertain significance rs57857456 GRCh37 Chromosome 13, 84452903: 84452903
43 SLITRK1 NM_052910.2(SLITRK1): c.*23G> A single nucleotide variant Uncertain significance rs200497030 GRCh38 Chromosome 13, 83879394: 83879394
44 SLITRK1 NM_052910.2(SLITRK1): c.*23G> A single nucleotide variant Uncertain significance rs200497030 GRCh37 Chromosome 13, 84453529: 84453529
45 SLITRK1 NM_052910.2(SLITRK1): c.-240delG deletion Uncertain significance rs886050337 GRCh37 Chromosome 13, 84455882: 84455882
46 SLITRK1 NM_052910.2(SLITRK1): c.-240delG deletion Uncertain significance rs886050337 GRCh38 Chromosome 13, 83881747: 83881747
47 SLITRK1 NM_052910.2(SLITRK1): c.-241dupT duplication Uncertain significance rs886050338 GRCh38 Chromosome 13, 83881748: 83881748
48 SLITRK1 NM_052910.2(SLITRK1): c.-241dupT duplication Uncertain significance rs886050338 GRCh37 Chromosome 13, 84455883: 84455883
49 SLITRK1 NM_052910.2(SLITRK1): c.-266delA deletion Uncertain significance rs886050340 GRCh37 Chromosome 13, 84455908: 84455908
50 SLITRK1 NM_052910.2(SLITRK1): c.-266delA deletion Uncertain significance rs886050340 GRCh38 Chromosome 13, 83881773: 83881773

Copy number variations for Gilles De La Tourette Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 60595 11 88300000 92800000 Copy number GRM5 Tourette syndrome
2 97401 16 1 7900000 Copy number A2BP1 Tourette syndrome
3 107550 17 15900000 22100000 Microdeletion Tourette syndrome
4 161233 22 17900000 22200000 Duplication COMT Tourette syndrome
5 204047 6 105500000 114600000 Copy number NKAIN2 Tourette syndrome
6 218083 7 107400000 127100000 Copy number IMMP2L Tourette syndrome
7 221370 7 143100000 147900000 Copy number CNTNAP2 Tourette syndrome
8 222485 7 152600000 155100000 Copy number DPP6 Tourette syndrome
9 257157 X 1 4300000 Deletion NLGN4 Tourette syndrome

Expression for Gilles De La Tourette Syndrome

Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for Gilles De La Tourette Syndrome

Pathways related to Gilles De La Tourette Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Histidine metabolism hsa00340

GO Terms for Gilles De La Tourette Syndrome

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 ADRA1A ADRA2A DRD2 DRD4 DRD5 HTR3B
2 dendrite GO:0030425 9.65 BDNF CNTNAP2 COMT DRD2 SGCE
3 integral component of membrane GO:0016021 9.5 AADAC ADRA1A ADRA2A CNTNAP2 COMT DBH
4 axon GO:0030424 9.35 BDNF CNTNAP2 COMT DRD2 SLC6A3

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.96 ADRA1A ADRA2A BDNF DRD2
2 response to drug GO:0042493 9.94 ADRA1A COMT DRD2 SLC6A3
3 locomotory behavior GO:0007626 9.8 DBH DRD2 SLC6A3
4 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.75 ADRA1A ADRA2A DRD2
5 synapse assembly GO:0007416 9.74 BDNF DRD2 SLITRK1
6 learning GO:0007612 9.73 CNTNAP2 COMT DRD5
7 modulation of chemical synaptic transmission GO:0050804 9.7 BDNF BTBD9 DRD2
8 response to cocaine GO:0042220 9.69 DRD2 DRD5 SLC6A3
9 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD4
10 transmission of nerve impulse GO:0019226 9.66 CNTNAP2 DRD5
11 response to pain GO:0048265 9.66 COMT DBH
12 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD5
13 response to iron ion GO:0010039 9.65 DRD2 SLC6A3
14 negative regulation of protein secretion GO:0050709 9.64 DRD2 DRD4
15 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD2 DRD5
16 negative regulation of voltage-gated calcium channel activity GO:1901386 9.63 DRD2 DRD4
17 prepulse inhibition GO:0060134 9.62 DRD2 SLC6A3
18 striatum development GO:0021756 9.61 CNTNAP2 DRD2
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD2 DRD4
20 associative learning GO:0008306 9.61 DBH DRD2 DRD5
21 adrenergic receptor signaling pathway GO:0071875 9.6 ADRA1A ADRA2A
22 regulation of dopamine metabolic process GO:0042053 9.59 DRD4 SLC6A3
23 adenohypophysis development GO:0021984 9.58 DRD2 SLC6A3
24 adult behavior GO:0030534 9.58 CNTNAP2 DRD2 SLITRK1
25 catecholamine biosynthetic process GO:0042423 9.55 DBH HDC
26 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.54 ADRA1A DRD5
27 dopamine receptor signaling pathway GO:0007212 9.54 DRD2 DRD4 DRD5
28 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.5 ADRA1A ADRA2A DRD2
29 fear response GO:0042596 9.49 DBH DRD4
30 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
31 response to histamine GO:0034776 9.46 DRD2 DRD4
32 behavioral response to ethanol GO:0048149 9.43 DBH DRD2 DRD4
33 dopamine metabolic process GO:0042417 9.33 COMT DRD2 DRD4
34 dopamine catabolic process GO:0042420 9.13 COMT DBH SLC6A3
35 response to amphetamine GO:0001975 8.92 DBH DRD2 DRD4 DRD5

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.72 ADRA1A ADRA2A DRD2 DRD4 DRD5
2 drug binding GO:0008144 9.61 DRD2 DRD4 SLC6A3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD4
4 epinephrine binding GO:0051379 9.37 ADRA2A DRD4
5 adrenergic receptor activity GO:0004935 9.33 ADRA1A ADRA2A DRD2
6 norepinephrine binding GO:0051380 9.26 ADRA2A DRD4
7 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
8 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Gilles De La Tourette Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....